Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ipsen SA announces positive results from phase IIa clinical study of Dysport in treatment of patients with Neurogenic Detrusor Overactivity (NDO)


Tuesday, 18 Mar 2014 02:30am EDT 

Ipsen SA:Positive results from phase IIa clinical trial assessing Dyspor in treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics.Results show that treatment with Dysport was associated with mean reduction from baseline of urinary incontinence episodes greater than 75 pct, 12 weeks after the injection, regardless of how drug is administered.These results were achieved with single dose of Dysport 750 Units injected in either 15 or 30 sites in detrusor muscle.Efficacy was confirmed by improvement in urodynamic parameters and quality of life.Safety profile observed in study is consistent with safety profile expected in this indication. 

Company Quote

33.05
-0.25 -0.75%
11:35am EDT